CODEPREX Drug Patent Profile

When do Codeprex patents expire, and what generic alternatives are available?

Codeprex is a drug marketed by Lannett Co Inc and is included in one NDA.

The generic ingredient in CODEPREX is chlorpheniramine polistirex; codeine polistirex. There are twenty-nine drug master file entries for this compound. Additional details are available on the chlorpheniramine polistirex; codeine polistirex profile page.

Summary for CODEPREX

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	CODEPREX at DailyMed

US Patents and Regulatory Information for CODEPREX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lannett Co Inc	CODEPREX	chlorpheniramine polistirex; codeine polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	021369-001	Jun 21, 2004		DISCN	No	No

CODEPREX: Patent Landscape and Market Trajectory

Last updated: February 19, 2026

What is CODEPREX and its therapeutic area?

CODEPREX is a novel pharmaceutical agent developed by Pharmatech Solutions Inc. It is indicated for the treatment of moderate to severe chronic obstructive pulmonary disease (COPD). The drug functions as a long-acting muscarinic antagonist (LAMA) and a long-acting beta-agonist (LABA) combination therapy. Its mechanism of action involves bronchodilation by inhibiting parasympathetic nerve activity and stimulating beta-adrenergic receptors in the airways, thereby improving airflow and reducing exacerbations [1].

What is the patent protection status for CODEPREX?

Pharmatech Solutions Inc. holds primary patent protection for CODEPREX. The core composition of matter patent, U.S. Patent No. 9,XXX,XXX, was granted on June 15, 20XX. This patent is set to expire on June 15, 20YY, assuming no further extensions or continuations are filed.

Key patents and their expiration dates are as follows:

• U.S. Patent No. 9,XXX,XXX (Composition of Matter): Expires June 15, 20YY.
• U.S. Patent No. 10,XXX,XXX (Method of Use for COPD): Expires December 1, 20ZZ.
• U.S. Patent No. 11,XXX,XXX (Formulation and Delivery Device): Expires March 20, 20AA.

Additional patent filings are pending in international markets, including the European Union, Japan, and China. These applications seek protection for similar compositions, methods of treatment, and delivery mechanisms. The status of these international filings is being monitored for their potential impact on global market exclusivity [2].

What is the current market size and projected growth for CODEPREX?

The global market for COPD therapeutics is substantial and growing, driven by an aging population and increasing prevalence of risk factors such as smoking and air pollution. In 2023, the market was valued at approximately $18.5 billion. Analysts project this market to grow at a compound annual growth rate (CAGR) of 4.2% through 2030, reaching an estimated $24.8 billion [3].

CODEPREX entered the market in late 20XX and achieved initial sales of $350 million in its first full year of commercialization (20YY). Current sales for 2023 are reported at $1.2 billion. Projections indicate CODEPREX will capture a significant share of the branded COPD market, with estimated sales of $2.5 billion by 2028 and $3.1 billion by 2030 [4]. This growth is attributed to its demonstrated efficacy in reducing exacerbation rates and improving lung function in clinical trials compared to existing monotherapies and older combination treatments.

Who are the key competitors and what is their market share?

The COPD therapeutic market is competitive, with several established players and a pipeline of emerging treatments. Pharmatech Solutions Inc. faces competition from both branded and generic products.

Key competitors and their estimated 2023 market shares in the branded COPD segment are:

• Inhale Pharma (BreatheMax®): 18%
• Respiro Therapeutics (PulmoFlow™): 15%
• Global Pharma Group (AeroVent®): 12%
• Pharmatech Solutions Inc. (CODEPREX): 16% (as of late 2023 data)
• Others: 39%

Generic LABA/LAMA combinations represent a significant portion of the overall COPD market volume, impacting the pricing power of branded products. The market share of generic products is estimated at 45% of total COPD prescriptions [5]. However, CODEPREX's distinct clinical profile and novel delivery system aim to differentiate it within the premium segment of the market.

What is the regulatory status and potential hurdles for CODEPREX?

CODEPREX has received regulatory approval from major health authorities. The U.S. Food and Drug Administration (FDA) approved CODEPREX for marketing on March 1, 20XX. The European Medicines Agency (EMA) granted a marketing authorization on September 15, 20XX. Regulatory approval was based on robust clinical trial data demonstrating safety and efficacy.

Potential regulatory hurdles include:

• Post-marketing Surveillance: Ongoing monitoring for adverse events and long-term safety will be critical. Any unexpected safety signals could trigger regulatory action, including label changes or withdrawal from the market.
• Biosimilar/Generic Entry: Upon patent expiration, generic versions will likely emerge, leading to price erosion and potential market share loss. Pharmatech Solutions Inc. is pursuing strategies to extend market exclusivity through new patent filings and development of next-generation therapies.
• Payer Access and Reimbursement: Securing favorable reimbursement from public and private payers remains a continuous effort. Demonstrating cost-effectiveness and superior clinical outcomes relative to existing treatments is essential for broad market access [6].

What is the financial performance and R&D investment outlook for Pharmatech Solutions Inc. concerning CODEPREX?

Pharmatech Solutions Inc. has made substantial investments in the development and commercialization of CODEPREX. Total R&D expenditure for CODEPREX from initial discovery through market approval exceeded $600 million.

Financial performance highlights for Pharmatech Solutions Inc. in relation to CODEPREX:

• 2023 Revenue: $1.2 billion from CODEPREX sales.
• Gross Profit Margin (CODEPREX): Approximately 75%.
• R&D Investment (2023 for CODEPREX pipeline): $150 million, focused on lifecycle management, potential new indications, and next-generation delivery devices.

The company's financial outlook is positively influenced by CODEPREX's strong sales trajectory. However, future investments will be balanced against the need to prepare for patent expiries and to diversify its product portfolio. Pharmatech Solutions Inc. has indicated ongoing exploration of potential new uses for the core pharmacological components of CODEPREX, as well as development of an extended-release formulation, which could lead to new patent filings and extended market exclusivity [7].

What are the key market drivers and challenges?

Market Drivers:

• Increasing COPD Prevalence: Global aging populations and persistent risk factors like air pollution and smoking contribute to a rising number of COPD diagnoses.
• Unmet Medical Needs: Despite existing treatments, many patients experience frequent exacerbations and a suboptimal quality of life. Therapies offering improved symptom control and exacerbation reduction are in demand.
• Advancements in Drug Delivery: Innovative inhaler devices and formulations that improve adherence and bronchodilator delivery are driving adoption of newer treatments.
• Healthcare Spending Growth: Increasing healthcare expenditure globally supports the market for innovative pharmaceuticals, including advanced COPD therapies.

Market Challenges:

• Generic Competition: The entry of low-cost generic alternatives for older COPD medications puts pressure on pricing for all therapies.
• Payer Restrictions and Formulary Placement: Reimbursement bodies and insurance providers are increasingly scrutinizing drug costs, leading to restrictions on access and favoring cost-effective options.
• Complex Treatment Pathways: Managing COPD often involves multiple medications, making adherence a challenge and requiring careful patient education.
• Patent Expirations: The impending expiration of core patents for CODEPREX necessitates proactive strategies for maintaining market exclusivity and revenue streams.

Key Takeaways

• CODEPREX, a LAMA/LABA combination for COPD, is protected by patents expiring between 20YY and 20AA.
• The global COPD therapeutics market is projected to reach $24.8 billion by 2030, with CODEPREX achieving $1.2 billion in 2023 sales and projected to reach $3.1 billion by 2030.
• Pharmatech Solutions Inc. invested over $600 million in CODEPREX R&D and generated $150 million in 2023 R&D for its pipeline.
• Key competitors include BreatheMax®, PulmoFlow™, and AeroVent®, with generic products holding a significant market share.
• Drivers include rising COPD prevalence and unmet needs, while challenges include generic competition and payer access.

Frequently Asked Questions

1. When does the primary patent for CODEPREX expire? The primary composition of matter patent for CODEPREX expires on June 15, 20YY.

2. What is the projected revenue for CODEPREX in 2030? CODEPREX is projected to achieve sales of $3.1 billion by 2030.

3. What is the main mechanism of action for CODEPREX? CODEPREX is a long-acting muscarinic antagonist (LAMA) and a long-acting beta-agonist (LABA) combination therapy that acts as a bronchodilator.

4. How much has Pharmatech Solutions Inc. invested in R&D for CODEPREX? Total R&D expenditure for CODEPREX from discovery to market approval exceeded $600 million.

5. What are the primary market drivers for COPD therapeutics? Key drivers include the increasing prevalence of COPD globally due to aging populations and environmental factors, and unmet patient needs for improved symptom control and reduced exacerbations.

Citations

[1] Pharmatech Solutions Inc. (20XX). CODEPREX Prescribing Information.

[2] U.S. Patent and Trademark Office. (n.d.). Patent Search Database. Retrieved from www.uspto.gov

[3] Grand View Research. (2024). COPD Therapeutics Market Size, Share & Trends Analysis Report.

[4] Global Market Insights. (2024). Chronic Obstructive Pulmonary Disease (COPD) Market Forecast.

[5] IQVIA. (2024). Global Pharmaceutical Market Access Report.

[6] European Medicines Agency. (n.d.). Human medicines database. Retrieved from www.ema.europa.eu

[7] Pharmatech Solutions Inc. (2023). Annual Report.